ATPW
RPRX icon

Ashton Thomas Private Wealth’s Royalty Pharma RPRX Stock Holding History

Ashton Thomas Private Wealth’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-147
Closed -$3.88K – 1576
2024
Q2 		$3.88K Buy
+147
New +$4.08K ﹤0.01% 1619

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ashton Thomas Private Wealth's RPRX Position: Q3 2024 in Review

Ashton Thomas Private Wealth sold out of Royalty Pharma (RPRX) in Q3 2024, closing a stake of 147 shares — an estimated $3.88K sold.

Ashton Thomas Private Wealth first reported a position in RPRX in Q2 2024 and held it in 1 quarter. The position peaked at $3.88K in Q2 2024. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

  • Ashton Thomas Private Wealth reported no remaining Royalty Pharma position as of Q3 2024 after selling out during the quarter.
  • Ashton Thomas Private Wealth sold 147 Royalty Pharma shares in Q3 2024, an estimated $3.88K.
  • Ashton Thomas Private Wealth first reported a position in Royalty Pharma in Q2 2024 and held it in 1 quarter.
  • Ashton Thomas Private Wealth's Royalty Pharma position peaked at $3.88K in Q2 2024.
  • 395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on Ashton Thomas Private Wealth's 13F filing for Q3 2024, filed 5 Nov 2024.